4:43AM ET 5/12/2022 MT NewswiresSurface Oncology (SURF) has an average rating of buy and price targets ranging from $10 to $14, according to analysts polled by Capital IQ. (MT Newswires...
8:13AM ET 4/14/2022 MT NewswiresSurface Oncology (SURF) said Thursday it has started two mid-stage trials on its experimental cancer drug SRF388 as a standalone therapy and as a part of a...
8:00AM ET 3/31/2022 MT NewswiresSurface Oncology (SURF) said Thursday that it has received a $30 million milestone payment as GlaxoSmithKline (GSK) has dosed the first patient in a phase...
7:43AM ET 12/15/2021 MT NewswiresSurface Oncology (SURF) said Wednesday it appointed Denice Torres as chair of the board of directors. Torres has been a board member of the company since...